|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP26B1 |
Gene summary for CYP26B1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP26B1 | Gene ID | 56603 |
| Gene name | cytochrome P450 family 26 subfamily B member 1 | |
| Gene Alias | CYP26A2 | |
| Cytomap | 2p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9NR63 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56603 | CYP26B1 | C04 | Human | Oral cavity | OSCC | 2.89e-03 | 2.95e-01 | 0.2633 |
| 56603 | CYP26B1 | C30 | Human | Oral cavity | OSCC | 3.73e-09 | 5.14e-01 | 0.3055 |
| 56603 | CYP26B1 | C51 | Human | Oral cavity | OSCC | 6.24e-08 | 5.68e-01 | 0.2674 |
| 56603 | CYP26B1 | SYSMH2 | Human | Oral cavity | OSCC | 4.32e-15 | 3.54e-01 | 0.2326 |
| 56603 | CYP26B1 | SYSMH3 | Human | Oral cavity | OSCC | 1.16e-25 | 5.74e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
| GO:00002801 | Oral cavity | OSCC | nuclear division | 237/7305 | 439/18723 | 9.62e-11 | 2.90e-09 | 237 |
| GO:000716318 | Oral cavity | OSCC | establishment or maintenance of cell polarity | 129/7305 | 218/18723 | 1.16e-09 | 2.86e-08 | 129 |
| GO:003052218 | Oral cavity | OSCC | intracellular receptor signaling pathway | 149/7305 | 265/18723 | 8.69e-09 | 1.81e-07 | 149 |
| GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
| GO:004211016 | Oral cavity | OSCC | T cell activation | 245/7305 | 487/18723 | 2.00e-07 | 3.22e-06 | 245 |
| GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| GO:00302166 | Oral cavity | OSCC | keratinocyte differentiation | 81/7305 | 139/18723 | 3.16e-06 | 3.81e-05 | 81 |
| GO:003001016 | Oral cavity | OSCC | establishment of cell polarity | 82/7305 | 143/18723 | 6.56e-06 | 7.24e-05 | 82 |
| GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
| GO:00099139 | Oral cavity | OSCC | epidermal cell differentiation | 109/7305 | 202/18723 | 1.08e-05 | 1.14e-04 | 109 |
| GO:00075849 | Oral cavity | OSCC | response to nutrient | 95/7305 | 174/18723 | 2.09e-05 | 1.99e-04 | 95 |
| GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
| GO:190370618 | Oral cavity | OSCC | regulation of hemopoiesis | 180/7305 | 367/18723 | 5.16e-05 | 4.30e-04 | 180 |
| GO:005086315 | Oral cavity | OSCC | regulation of T cell activation | 161/7305 | 329/18723 | 1.44e-04 | 1.02e-03 | 161 |
| GO:00300983 | Oral cavity | OSCC | lymphocyte differentiation | 179/7305 | 374/18723 | 2.74e-04 | 1.74e-03 | 179 |
| GO:00723296 | Oral cavity | OSCC | monocarboxylic acid catabolic process | 66/7305 | 122/18723 | 5.02e-04 | 2.95e-03 | 66 |
| GO:19021059 | Oral cavity | OSCC | regulation of leukocyte differentiation | 136/7305 | 279/18723 | 5.53e-04 | 3.21e-03 | 136 |
| GO:005087819 | Oral cavity | OSCC | regulation of body fluid levels | 179/7305 | 379/18723 | 6.19e-04 | 3.50e-03 | 179 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP26B1 | SNV | Missense_Mutation | c.1386N>G | p.Ser462Arg | p.S462R | Q9NR63 | protein_coding | deleterious(0) | possibly_damaging(0.786) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CYP26B1 | SNV | Missense_Mutation | c.796N>A | p.Ala266Thr | p.A266T | Q9NR63 | protein_coding | deleterious(0) | benign(0.103) | TCGA-AN-A0XV-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CYP26B1 | SNV | Missense_Mutation | novel | c.146N>C | p.Ile49Thr | p.I49T | Q9NR63 | protein_coding | deleterious(0) | benign(0.028) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CYP26B1 | SNV | Missense_Mutation | c.964N>A | p.Leu322Met | p.L322M | Q9NR63 | protein_coding | tolerated(0.11) | probably_damaging(0.968) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| CYP26B1 | SNV | Missense_Mutation | c.712N>G | p.Gln238Glu | p.Q238E | Q9NR63 | protein_coding | deleterious(0.01) | benign(0.027) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYP26B1 | SNV | Missense_Mutation | c.1090N>A | p.Leu364Met | p.L364M | Q9NR63 | protein_coding | tolerated(0.09) | possibly_damaging(0.656) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CYP26B1 | SNV | Missense_Mutation | c.55N>A | p.Leu19Met | p.L19M | Q9NR63 | protein_coding | deleterious(0.01) | probably_damaging(0.977) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYP26B1 | SNV | Missense_Mutation | c.421N>G | p.Lys141Glu | p.K141E | Q9NR63 | protein_coding | deleterious(0.01) | benign(0.015) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CYP26B1 | SNV | Missense_Mutation | novel | c.265N>G | p.Leu89Val | p.L89V | Q9NR63 | protein_coding | deleterious(0.01) | possibly_damaging(0.524) | TCGA-AA-3872-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| CYP26B1 | SNV | Missense_Mutation | c.226C>T | p.Arg76Trp | p.R76W | Q9NR63 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 56603 | CYP26B1 | DRUGGABLE GENOME, CYTOCHROME P450, ENZYME | TALAROZOLE | TALAROZOLE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |